Skip Navigation LinksNBS-Disorders-Detectable

Newborn Screening program

California Expands Screening for Newborn Disorders. The California Newborn Screening (NBS) Program now includes screening for Guanidinoacetate Methyltransferase (GAMT) and Mucopolysaccharidosis Type 2 (MPS 2).​​

Detectable Disorders by Newborn Screening

The California Newborn Screening (NBS) Program provides newborn screening to all California babies. For a full list of core conditions and secondary conditions, please see our Recommended Uniform Screening Panel (RUSP) webpage. 

Please Note: due to biological variability of newborns and differences in detection rates for the various disorders in the newborn period, the California Newborn Screening Program will not identify all newborns with these conditions. While a positive screening result identifies newborns at an increased risk to justify a diagnostic work-up, a negative screening result do​​es not rule out the possibility of a disorder. 

Health care providers should remain watchful for any sign or symptoms of these disorders in their patients. A newborn screening result should not be considered diagnostic, and cannot replace the individualized evaluation and diagnosis of an infant by a well-trained, knowledgeable health care provider.​

​See below for a list of RUSP disorders, with their definitions and links to helpful resources where available.​​​​​​​​

Definitions and Resources

Page Last Updated :